FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start.
- Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start.
- For the first time, we have a treatment that targets complement-mediated hemolysis, which is the underlying cause of the red blood cell destruction in many CAD patients.
- Dosage interruptions due to an adverse reaction occurred in 17 percent (4/24) of patients who received Enjaymo.
- Following the completion of the 26-week treatment period of CARDINAL (Part A), eligible patients continued to receive Enjaymo in an extension study.